This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

FDA Seeks More Safety Data on Intrinsa

Updated from 5:21 p.m. EDT

An advisory committee of the Food and Drug Administration said Thursday that an experimental drug to increase women's sexual desire will need more study of its long-term safety before the panel could recommend approval.

The panel voted unanimously that the FDA should reject the product.

The committee of experts said that although the drug Intrinsa, a transdermal patch that transmits the hormone testosterone, is effective, the company's developer hadn't provided enough information about the drug's long-term safety. The drug is made by Procter & Gamble (PG), under license from Watson Pharmaceuticals (WPI).

Many Wall Street analysts had speculated that Intrinsa could be the female version of Viagra, the erectile dysfunction drug made by Pfizer (PFE).

P&G was asking the advisory committee to approve the drug designed to improve sexual desire in menopausal women whose ovaries have been surgically removed. The FDA isn't bound by its advisory committees' opinions, but the agency usually follows their recommendations.

Intrinsa would be the first FDA-approved drug to treat the condition called hypoactive sexual desire disorder. Other companies are working on female sexual disorder products such as patches, pills, gels, creams and nasal sprays.

The decision is a setback not only to P&G and to Watson but also to a host of other companies that are working on drugs to treat diminished sexual desire in women. The advisory panel's announcement came after markets had closed.

P&G's stock closed up $1.16, or 2.1%, to $55.82 in regular trading. But it gave back 71 cents, or 1.3%, in after-hours trading. Watson's stock closed at $29.30, gaining 23 cents, or 0.8%, in regular trading.

The biggest loser was BioSante Pharmaceuticals (BPA), which is developing a testosterone gel. In regular trading, the company's stock lost 90 cents, or 10.7%, to $7.50. In after-hours trading, the stock was beaten down by $2.50, or 33.3%, to $5.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs